Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Abstract Receives “BEST ABSTRACTS AWARD FOR CLINICAL RESEARCH” at 2012 BMT Tandem Meetings on February 3rd, 2012
RESEARCH TRIANGLE PARK, NC, January 25, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that final data from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV), has been accepted for oral presentation at the BMT Tandem Meetings on February 1-5, 2012, in San Diego, California. CMX001 is a broad spectrum, Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of CMV in hematopoietic cell transplant (HCT) recipients. In total, three abstracts related to CMX001 have been accepted for presentation at the 2012 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT)….
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.